• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Novo-Nordisk News

    118,63 € 0,00% +0,00 €
    11:18:31 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EU6F
    ISIN: DK0062498333
    US-Symbol: NONOF
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 9,48
    VM9PJ5

    Unternehmensmeldungen

    25.03.24 - GlobeNewswire
    Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
    Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for ...
    31.01.24 - GlobeNewswire
    Novo Nordisk files annual report with the SEC
    Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange ...
    04.01.24 - GlobeNewswire
    Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
    Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management Cellarity collaboration will build ...
    23.11.23 - GlobeNewswire
    Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
    Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 2023 1 to expand the ...
    10.11.23 - GlobeNewswire
    Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
    Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 2023 1 to expand existing manufacturing ...
    10.08.23 - GlobeNewswire
    Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
    Bagsværd, Denmark and Montreal, Canada, 1 0 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up ...
    12.06.23 - GlobeNewswire
    Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark
    Bagsværd , Denmark, 12 June 2023 - Novo Nordisk today announced plans to invest 15.9 billion Danish kroner starting in 2023 1 to expand an existing Active Pharmaceutical ...
    05.06.23 - GlobeNewswire
    Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares
    Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP, representing 45.3 % of its share ...
    24.05.23 - GlobeNewswire
    Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
    Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250- 335 million US dollars for each of seven development programmes , as well as ...
    12.04.23 - GlobeNewswire
    Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
    Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and ...
    02.03.23 - GlobeNewswire
    Novo Nordisk to expand R&D presence in greater Boston area
    Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of ...
    10.02.23 - GlobeNewswire
    Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure
    HS-001 consist s of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs) .
    01.02.23 - GlobeNewswire
    Novo Nordisk files annual report with the SEC
    Bagsværd , Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022 on Form 20-F for the financial year 2022 with the US Securities and Exchange ...
    22.11.22 - GlobeNewswire
    Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
    Bagsværd , Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also ...
    14.10.22 - GlobeNewswire
    Novo Nordisk announces the completion of the Forma Therapeutics acquisition
    Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has ...
    12.09.22 - GlobeNewswire
    Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
    Bagsværd, Denmark and Redmond , W A , US , 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational ...
    01.09.22 - GlobeNewswire
    Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
    Bagsværd, Denmark and Watertown, M ass, US , 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have ...
    26.06.21 - GlobeNewswire
    Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
    Bagsv æ rd , Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic ® (semaglutide) provided statistically significant ...
    09.04.19 - DGAP
    Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
    Hardman & Co Research Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales 09-Apr-2019 / 16:10 GMT/BST
    05.02.19 - GlobeNewswire
    Novo Nordisk files annual report with the SEC
    Bagsværd, Denmark, 5 February 2019 - Novo Nordisk A/S has filed its Annual Report 2018 on Form 20-F for the financial year 2018 with the US Securities and Exchange ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »